TD Cowen Forecasts Strong Price Appreciation for Revvity (NYSE:RVTY) Stock

Revvity (NYSE:RVTY) had its price objective lifted by equities researchers at TD Cowen from $175.00 to $185.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen‘s price target would suggest a potential upside of 14.46% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Royal Bank Of Canada increased their target price on shares of Revvity from $135.00 to $172.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Weiss Ratings upgraded Revvity from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Bank of America restated a “neutral” rating on shares of Revvity in a research report on Wednesday. UBS Group initiated coverage on Revvity in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 target price for the company. Finally, KeyCorp boosted their price target on shares of Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Six analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $128.86.

Revvity Stock Performance

Revvity stock traded down $1.85 during mid-day trading on Wednesday, hitting $161.63. 1,568,589 shares of the company’s stock traded hands, compared to its average volume of 1,535,757. Revvity has a one year low of $81.22 and a one year high of $171.74. The company has a market cap of $18.04 billion, a PE ratio of 76.93, a price-to-earnings-growth ratio of 2.76 and a beta of 1.08. The firm has a 50 day moving average price of $145.89 and a 200 day moving average price of $112.62. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.08. The business had revenue of $728.90 million for the quarter, compared to analysts’ expectations of $694.73 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.18 EPS. On average, equities analysts forecast that Revvity will post 5.36 EPS for the current year.

Insider Buying and Selling

In other news, insider Tajinder Vohra sold 7,330 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the sale, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. The trade was a 52.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 9,045 shares of company stock valued at $1,281,439. Insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Revvity

A number of large investors have recently added to or reduced their stakes in RVTY. Public Employees Retirement System of Ohio purchased a new stake in shares of Revvity in the 2nd quarter valued at about $3,845,000. The Manufacturers Life Insurance Company increased its position in shares of Revvity by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company’s stock worth $41,048,000 after purchasing an additional 20,278 shares during the last quarter. Wellington Management Group LLP raised its stake in Revvity by 10,653.8% in the second quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock valued at $96,304,000 after purchasing an additional 857,526 shares in the last quarter. Tocqueville Asset Management L.P. purchased a new stake in Revvity in the second quarter valued at approximately $4,791,000. Finally, State Street Corp lifted its position in Revvity by 0.8% during the second quarter. State Street Corp now owns 4,342,739 shares of the company’s stock valued at $483,173,000 after purchasing an additional 32,426 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity News Summary

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported Q3 adjusted EPS of $1.38, above the roughly $1.30 consensus, and revenue of $728.9 million versus estimates of about $694.7 million. Revenue grew 4.3% year over year, with Life Sciences strength and margin expansion contributing to the beat. The company also raised its 2026 outlook. Q3 earnings beat and outlook
• Positive Sentiment: CFRA upgraded RVTY from Hold to Buy, adding a favorable analyst view after the results. CFRA upgrade
• Neutral Sentiment: Royal Bank of Canada raised its price target from $135 to $172 but retained a Sector Perform rating; the new target implied about 6.3% upside at the cited share price. RBC price target
• Neutral Sentiment: Some coverage questioned whether the stock is now expensive after its earnings-driven run. That concern may limit further gains, particularly given the high valuation noted in the provided market data. Dividend and valuation discussion

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.